2014 CME Symposia - Lunch Symposium C
Register for the CMHC today to sign up for these value-added CME/CE activities-at no additional cost!
Pre-registration for symposia will open at the end of August for CMHC registrants to make selections. There are no additional fees to attend. Symposia include meals or refreshments and seating is limited and on a first-come, first-serve basis.
Lunch Symposium C
Thursday · 12:45 - 2:15pm
Evolving Strategies for LDL-Lowering: Novel Targets and Treatments for CVD Risk Reduction
Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals
The latest CVD prevention guidelines published by national organizations have diverted significantly from previous recommendations in that they abandoned target goals for lipid parameters in favor of focusing on statin treatment for high-risk patients. While statins remain first-line therapy in LDL-C reduction, patients continue to experience residual risk or are unable to tolerate statins.
Recent insights into LDL receptor recycling revealed novel therapeutic mechanisms demonstrating significant LDL-C reductions, which have led to a number of new therapies under development. During this symposium, faculty will review the most recent data on these new approaches to LDL-C reduction, including inhibition of PCSK9, apolipoprotein-B100 (apoB), CETP and MTP. A concluding panel discussion will address the clinical implications of these emerging therapies in patients with high residual risk, severe/familial hypercholesterolemia or as an alternative for patients who are intolerant to statins.
- Appraise recent guidelines on lipid management and strategies for effective screening, diagnosis, and management of individuals with severe and/or resistant hypercholesterolemia.
- Evaluate pharmacologic treatment options that are available to overcome limitations posed by statin therapy.
- Review the pathogenesis of atherosclerosis and the role of LDL receptor function and removal in cholesterol homeostasis.
- List genetic variants that cause an increase in LDL-C levels and the mechanistic rationale for lowering LDL-C through PCSK9 and apoB inhibition.
- Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk.
Preliminary Agenda & Faculty
|12:45 - 12:50pm
||Introduction and Opening Remarks
||Chairperson: Terry A. Jacobson, MD
|12:50 - 1:10pm
||Addressing the Unmet Need for LDL Targeted Atheroprotection in High Risk Populations
||Presenter: Eliot A. Brinton, MD
|1:10 - 1:30pm
||Genetic Insights into Mechanisms Underlying Regulation of LDL-C
||Presenter: Sekar Kathiresan, MD
|1:30 - 1:55pm
||Clinical Evidence for New Therapeutic Approaches to LDL-C Lowering
||Presenter: Evan A. Stein, MD, PhD
|1:55 - 2:15pm
||A Look Ahead: Clinical Implications of New LDL-C Lowering Therapies to the Clinic-Panel Discussion and Q&A
||Moderator: Terry A. Jacobson, MD
Discussants: Eliot A. Brinton, MD; Sekar Kathiresan, MD; Evan A. Stein, MD, PhD
Terry A. Jacobson, MD
- President, National Lipid Association
- Professor of Medicine, Emory University Director
- Office of Health Promotion & Disease Prevention
- Co-Director, Lipid & CV Risk Reduction Program
- Grady Health Systems
- Atlanta, GA
Eliot A. Brinton, MD
- Director, Atherometabolic Research
- Utah Foundation for Biomedical Research
Sekar Kathiresan, MD
- Associate Professor of Medicine
- Harvard Medical School
- Director, Preventive Cardiology
- Massachusetts General Hospital
- Boston, MA
Evan A. Stein, MD, PhD
- Director Emeritus
- Metabolic & Atherosclerosis Research Center
View Complete Accreditation Details and Program Overview: CMHC Accreditation